INTRODUCTION: @entity2265 in @entity740 ( @entity740 ) is considered as an independent risk factor for surrogate clinical end points like @entity729 ( @entity729 ) and @entity79 , or hard clinical outcomes like @entity65 . Various treatment options are available for @entity4613 removal or reduction. @entity460 -based @entity4613 binders (CBB) with their possible positive @entity460 balance became culprits for progressive @entity729 and increased mortality risk. Non- @entity460 -based binders (NCBB) treatment allowed a comparable control of @entity2265 with a lower risk of @entity2741 and a slower progression of @entity729 . Recent data have shown a 22% risk reduction in all-cause mortality with NCBB compared to CBB treatment. The appropriate timing of @entity4613 binder initiation in @entity740 @entity1 is still unclear. Recent reports in @entity1 with @entity740 stages 3b-4 showed increased @entity729 progression when actively treated compared to placebo and a positive @entity460 , but no negative @entity4613 balance. Areas covered: This review discusses the advantages and disadvantages of the pharmacological options to treat @entity2265 . Expert opinion: The use of @entity4613 binders is essential in preventing morbidity and mortality in dialysis @entity1 . The choice of @entity4613 binder takes into account @entity740 stage, the presence of other components of @entity740 , concomitant therapies and drug side-effect profile.

Advances in pharmacotherapy for XXXX in renal disease.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2741 :: ('MESH:D006934', 'Disease') :: ['hypercalcemia'] @entity4613 :: ('D010710', 'Chemical') :: ['phosphate'] @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'chronic kidney disease', 'CKD-mineral and bone disorders'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone disease'] @entity2265 :: ('MESH:D054559', 'Disease') :: ['hyperphosphatemia', 'Hyperphosphatemia'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium', 'Calcium'] @entity729 :: ('MESH:D061205', 'Disease') :: ['vascular calcification', 'VC'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular events']
@entity2265 :: (MESH:D054559,Disease) :: ['hyperphosphatemia']
